阿斯利康超出了顶线和底线预期;重申25财年前景

2025-07-29 14:15

AstraZeneca press release (NASDAQ:AZN): Q2 Non-GAAP EPS of $2.17 beats by $1.07.
Revenue of $14.46B (+11.7% Y/Y) beats by $360M.
Interim dividend increased 3% to $1.03 (76.7 pence, 9.81 SEK).
Guidance: AstraZeneca reiterates its Total Revenue and Core EPS guidance4 for FY 2025 at CER, based on the average foreign exchange rates through 2024.
Total Revenue is expected to increase by a high single-digit percentage vs. estimated growth of 6.75% Y/Y; Core EPS is expected to increase by a low double-digit percentage vs. estimated growth of 8.17% Y/Y.
The Core Tax rate is expected to be between 18-22%.
"As we enter our next phase of growth, we have pledged $50 billion to continue to grow in the US, which includes the largest manufacturing investment in AstraZeneca’s history, set for Virginia. This landmark investment reflects not only America’s importance but also our confidence in our innovative medicines to transform global health and power AstraZeneca’s ambition to deliver $80 billion revenue by 2030.”

More on AstraZeneca